Literature DB >> 11246343

Update on the pathologic approach to the diagnosis of gastritis, gastric atrophy, and Helicobacter pylori and its sequelae.

P Sipponen1.   

Abstract

Biopsy sampling of the gastric mucosa at diagnostic endoscopy provides information that cannot be obtained otherwise. The most common indication for gastric biopsy is the need to know whether the patient is infected with Helicobacter pylori or not and whether the stomach is gastritic or not. Microscopic examination of gastric biopsy specimens gives, in addition to H. pylori status, information about the grade, extent, and topography of gastritis- and atrophy-related alterations in the gastric mucosa. This information provides further possibilities for the assessment of risk and likelihood of various gastric disorders. The presence of atrophy (loss of mucosal glands) results in failures in secretory functions of the corresponding mucosa and leads to errors in the homeostasis of normal gastric physiology. The grade of atrophy of the corpus mucosa linearly correlates with peak and maximal output of acid. The presence of advanced (moderate or severe) corpus atrophy indicates an extremely hypochlorhydric or achlorhydric stomach in which, for example, ordinary peptic ulcer is unlikely or impossible in spite of a possible H. pylori infection. Some well characterized and common topographic phenotypes of H. pylori gastritis and atrophic gastritis can be delineated as follows: Predominance or restriction of the H. pylori-related inflammation in antrum, in association with a nonatrophic corpus mucosa--of which phenotype is the most common--and with an increased risk of peptic ulcer disease, duodenal ulcer in particular ("duodenal ulcer phenotype" of gastritis); the presence of atrophic gastritis in corpus of the stomach ("corpus predominant gastritis"), which indicates a low risk of peptic ulcer and a reduction in the capacity of the patient to secrete acid; the occurrence of advanced atrophic gastritis and intestinal metaplasia multifocally in the stomach (advanced "multifocal atrophic gastritis"), which are features of a gastritis type and which also indicate a low acid secretion capacity and an increased risk of gastric neoplasias ("gastric cancer phenotype of gastritis"), suggesting a need for a careful exclusion of concomitant presence of small focal neoplastic or dysplastic lesions; and the presence of normal and healthy gastric mucosa, which indicates an extremely low risk of both peptic ulcer disease or gastric cancer and, therefore, is a finding of high clinical relevance. The presence of duodenal or gastric ulcer in conjunction with normal, healthy gastric mucosa suggests either aspirin or nonsteroidal antiinflammatory drugs to be the most likely cause of the ulcer.

Entities:  

Mesh:

Year:  2001        PMID: 11246343     DOI: 10.1097/00004836-200103000-00003

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  12 in total

1.  Chromoendoscopic evaluation of gastric mucosa after partial gastrectomy by use of modified endoscopic Congo red test.

Authors:  Ervin Tóth; Kristina Sjölund; Henrik Thorlacius
Journal:  World J Surg       Date:  2003-05-13       Impact factor: 3.352

2.  Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus.

Authors:  Tan Han Loong; Ngiu Chai Soon; Nik Ritza Kosai Nik Mahmud; Jeevinesh Naidu; Rafiz Abdul Rani; Nazefah Abdul Hamid; Marjanu Hikmah Elias; Isa Mohamed Rose; Azmi Tamil; Norfilza M Mokhtar; Raja Affendi Raja Ali
Journal:  Biomed Rep       Date:  2017-09-20

3.  Regular arrangement of collecting venules: Does patient age affect its accuracy?

Authors:  Alshimaa Alaboudy; Ashraf Elbahrawy; Shigemi Matsumoto; Ghada M Galal; Tsutomu Chiba
Journal:  World J Gastrointest Endosc       Date:  2011-06-16

4.  Dyspepsia-Like Symptoms in Helicobacter pylori-Negative Chronic Gastritis are Associated with ASCA-, ANCA-, and Celiac Seropositivity but Not with Other Autoimmune Parameters: A Single-Centre, Retrospective Cross-Sectional Study.

Authors:  Noémi Zádori; Dávid Németh; Levente Frim; Nóra Vörhendi; Lajos Szakó; Szilárd Váncsa; Péter Hegyi; József Czimmer
Journal:  Int J Gen Med       Date:  2022-10-12

5.  A comparison study of gastric cancer risk in patients with duodenal and gastric ulcer: roles of gastric mucosal histology and p53 codon 72 polymorphism.

Authors:  Zun-Wu Zhang; Paul Newcomb; Andrew Hollowood; Jyoti Gupta; Roger Feakins; Alan Storey; Michael J G Farthing; Derek Alderson; Jeff Holly
Journal:  Dig Dis Sci       Date:  2004-02       Impact factor: 3.199

6.  Severe gastritis decreases success rate of Helicobacter pylori eradication.

Authors:  Ismail Hakki Kalkan; Ferdane Sapmaz; Sefa Güliter; Pınar Atasoy
Journal:  Wien Klin Wochenschr       Date:  2015-12-04       Impact factor: 1.704

Review 7.  The risk of gastric cancer in patients with duodenal and gastric ulcer: research progresses and clinical implications.

Authors:  Zunwu Zhang
Journal:  J Gastrointest Cancer       Date:  2007

8.  Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa.

Authors:  Hae Yeon Kang; Nayoung Kim; Young Soo Park; Jin-Hyeok Hwang; Jin-Wook Kim; Sook Hyang Jeong; Dong Ho Lee; Hyun Chae Jung; In Sung Song
Journal:  Dig Dis Sci       Date:  2006-11-01       Impact factor: 3.487

9.  The diagnostic value of endoscopy and Helicobacter pylori tests for peptic ulcer patients in late post-treatment setting.

Authors:  Heidi-Ingrid Maaroos; Helena Andreson; Krista Lõivukene; Pirje Hütt; Helgi Kolk; Ingrid Kull; Katrin Labotkin; Marika Mikelsaar
Journal:  BMC Gastroenterol       Date:  2004-10-26       Impact factor: 3.067

10.  Helicobacter pylori and precancerous conditions of the stomach: the frequency of infection in a cross-sectional study of 79 consecutive patients with chronic antral gastritis in Yaoundé, Cameroon.

Authors:  Firmin Ankouane; Dominique Noah Noah; Félicien Ntoné Enyime; Carole Menzy Ndjollé; Roger Nsenga Djapa; Bernadette Ngo Nonga; Oudou Njoya; Elie Claude Ndjitoyap Ndam
Journal:  Pan Afr Med J       Date:  2015-01-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.